S 2292 · 112th Congress 2011–2013, ended

PATIENTS' FDA Act

Latest action · Apr 17, 2012 Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Progress

Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.

  1. IntroducedApr 17, 2012
  2. Passed SenateNot reached
  3. Passed HouseNot reached
  4. To the PresidentNot reached
  5. Became lawNot reached

Summary

Promoting Accountability, Transparency, Innovation, Efficiency, and Timeliness at FDA Act of 2012 or the PATIENTS' FDA Act - Requires the Secretary of Health and Human Services (HHS) to develop a strategy and implementation plan for advancing regulatory science for medical products in order to promote the public health and advance innovation in regulatory decision making.

Expands reporting requirements related to Food and Drug Administration (FDA) progress reports, generic drugs, and biosimilar products.

Requires the Secretary to: (1) document the scientific and regulatory rationale for any significant decision regarding drugs, biologics, or medical device applications; and (2) review all regulations and guidance of the FDA with respect to human medical products to ensure consistency with the requirements of the Federal Food, Drug, and Cosmetic Act (FFDCA) and specified regulatory principles.

Amends the FFDCA to require the Secretary to assess the safety and effectiveness of a medical device from the perspective of a reasonable patient in the intended use population.

Sets forth provisions governing determinations by the Secretary of a lack of reasonable assurance of safety of a device.

Requires the Secretary to implement a structured benefit-risk assessment framework in the new drug approval process.

Directs the FDA to foster and encourage uniform, scientifically-driven clinical trial standards around the world.

Sets forth provisions governing investigational exemptions for medical devices.

Requires the  Office of the Chief Counsel in the FDA to review a warning letter with respect to a drug or device before it is issued.

Sets forth provisions related to FDA advisory committees.

Revises provisions governing medical devices, including to require the Secretary to: (1) assign a tracking number to a medical device and assign an experienced reviewer to review the application; (2) revise the device submission acceptance criteria; and (3) regularly publish detailed decision summaries for each clearance of a device, substantial equivalence determination for a device, and each initial classification of a device. Sets forth the circumstances under which a medical device classification report must be submitted for a modification of a device.

Exempts medical devices modified to meet the individual needs of a specific patient from requirements to meet specified performance standards and premarket approval clearance if specified requirements are met.

Revises and extends through October 1, 2017, provisions authorizing accredited persons to provide classification reports for a medical device and to inspect class II or class III device facilities.

Requires the Secretary to submit a strategic integrated management plan for the Center for Drug Evaluation and Research, the Center for Biologics Evaluation and Research, and the Center for Devices and Radiological Health.

Directs the Secretary to contract with a consulting firm to conduct a comprehensive assessment of the process for the review of drug, device, and biologics applications.

Requires the Comptroller General to report on activities under this Act.

Cosponsors 1

Members who signed on, in the order they did. All signed on Apr 17, 2012.

SeatCosponsorSigned on
R-OKTom CoburnOriginalApr 17, 2012

Committees 1

Where it was sent and what each committee and subcommittee did with it, in order.

ChamberCommitteeWhat it did
SenateHealth, Education, Labor, and Pensions Committee
Referred Apr 17, 2012

Actions 2

Everything that happened, newest first.

  1. Apr 17, 2012Introduced in Senate
  2. Apr 17, 2012Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

In the Congressional Record 1

Days the Record’s own index lists this bill, newest first, with the pages and the members it names. Pages starting H are the House, S the Senate, E Extensions of Remarks.

WhereIn the RecordMembersDate
SenateDebate and remarks S4616, S4625Richard Burr R-NC, Tom Harkin D-IAJun 26, 2012

Titles 3

Every title it has carried, official and short, at each stage.

Official Title as Introduced
A bill to promote accountability, transparency, innovation, efficiency, and timeliness at the Food and Drug Administration for America's patients.
Short Titles as Introduced
PATIENTS' FDA Act
Promoting Accountability, Transparency, Innovation, Efficiency, and Timeliness at FDA Act of 2012

Subjects

Assigned by the Library of Congress. Policy area: Health.

Text 1

Each version as it was printed, newest first.

  1. Apr 17, 2012Introduced in Senate

Support LegiList

This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.

Processed by Stripe in a separate window. LegiList never sees card details.

Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.